September 18, 2021
Company Info
| Industry | Drugstore Chains |
|---|---|
| Sector | Retail Trade |
| Employees | 219 |
| CEO | Mr. Matthew N. Hulett |
| Address | 420 South Congress Avenue , Delray Beach, FL 33445 |
|---|---|
| Phone | 1.561.526.4444 |
| Website | www.1800petmeds.com |
PetMed Express, Inc. engages in the provision of markets prescription and non-prescription pet medications, health products and supplies for dogs and cats. Its non-prescription medications include flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies. The prescription medications include heartworm preventatives, arthritis, thyroid, diabetes and pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. The firm markets its products through national television, online and direct mail or print advertising campaigns. The company was founded in January 1996 and is headquartered in Delray Beach, FL.
Competitors
| Company Name | 3 Month %Change |
1 Year %Change |
|---|---|---|
| PetMed Express, Inc. | -17.31% | -11.43% |
| Rite Aid Corp. | -18.12% | 31.72% |
| Missfresh Ltd. | n/a | n/a |
| Shoe Carnival, Inc. | 5.03% | 78.32% |
| Zumiez, Inc. | -3.01% | 38.87% |
Statement Summary
as of 4:00 ET PM 09/16/2021| Total Assets (MRQ) | 173.3 M |
|---|---|
| Total Liabilities (MRQ) | 33.0 M |
| Shareholders’ Equity (MRQ) | 140.3 M |
| Total Revenue (Annual) | 79.3 M |
| Net Income (Annual) | 4.4 M |
Earnings And Estimates
as of 4:00 ET PM 09/16/2021
| Current Qtr EPS Estimate | 0.37 |
|---|---|
| Current FY EPS Estimate | 1.33 |
| Long Term EPS Growth Estimate | 13.00 |
| Next Expected Earnings Date | 10/25/2021 |
PETS vs S&P 500
as of 09/16/2021| Relative To S&P 500 |
PETS | |
|---|---|---|
| 4 Weeks | n/a | n/a |
| 12 Weeks | n/a | n/a |
| YTD | n/a | n/a |
Earnings Surprises
as of 4:00 ET PM 09/16/2021| Fiscal Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 06/2021 | 0.37 | 0.22 | -40.54% |
| 03/2021 | 0.41 | 0.34 | -16.73% |
| 12/2020 | 0.39 | 0.38 | -1.72% |
| 09/2020 | 0.41 | 0.42 | +3.64% |
| 06/2020 | 0.39 | 0.39 | +0.86% |
| 03/2020 | 0.29 | 0.35 | +19.70% |
| 12/2019 | 0.30 | 0.34 | +13.33% |
| 09/2019 | 0.26 | 0.33 | +26.92% |
Financial Strength
as of 4:00 ET PM 09/16/2021| Pre-Tax Margin | 7.30 |
|---|---|
| Net Margin | -30.86 |
| Operating Margin | 6.83 |
| Return On Equity | 19.96 |
| Return On Assets | 16.22 |
| Inventory Turnover (TTM) | 5.81 |
| Sales Growth (MRQ) | 5.67 |
Ratios
as of 4:00 PM ET 09/16/2021| Price/Earnings (TTM) | 19.80 |
|---|---|
| Price/Book (MRQ) | 3.88 |
| Price/Cash Flow (TTM) | 10.68 |
| Book Value (MRQ) | 6.92 |
| Quick Ratio (MRQ) | 3.70 |
| Current Ratio (MRQ) | 4.62 |
| Total Debt/Equity (MRQ) | 0.00 |
Short Interest
as of 4:00 PM ET 09/17/2021| % Short - 0.00% | |
| % Remaining Float - 100.00% |
| Current | Last Month | |
|---|---|---|
| Short Interest Date | n/a | n/a |
| Short Interest Shares | 0 | 0 |
| Short Interest Ratio | 0.0 | 0.0 |
M Y M Y
Total Assets 0,0.00 0,0.00
Total Liabilities 0,0.00 0,0.00
Total Equity 0,0.00 0,0.00
M Y M Y
Total Revenue 0,0.00 0,0.00
EBT Exc.
Unusual Items
0,0.00
0,0.00
Net Income 0,0.00 0,0.00
M Y M Y
Cash from
Operations
0,0.00
0,0.00
Cash from
Activities
0,0.00
0,0.00
Cash from
Fin. Activities
0,0.00
0,0.00
TOTAL ASSETS |
TOTAL LIABILITIES |
TOTAL EQUITY |
|---|---|---|
Balance Sheet
| M Y | ||||
|---|---|---|---|---|
| ASSETS | ||||
| Cash And Equivalents | 0,0.00 | |||
| Receivables | 0,0.00 | |||
| Inventories | 0,0.00 | |||
| Other Current Assets | 0,0.00 | |||
| Total Current Assets | 0,0.00 | |||
| Property, Plant & Equipment, Gross | 0,0.00 | |||
| Accumulated Depreciation & Depletion | 0,0.00 | |||
| Property, Plant & Equipment, Net | 0,0.00 | |||
| Intangibles | 0,0.00 | |||
| Other Non-Current Assets | 0,0.00 | |||
| Total Non-Current Assets | 0,0.00 | |||
| TOTAL ASSETS | 0,0.00 | |||
| Liabilities & Shareholder Equity | ||||
| Accounts Payable | 0,0.00 | |||
| Short Term Debt | 0,0.00 | |||
| Total Current Liabilities | 0,0.00 | |||
| Long Term Debt | 0,0.00 | |||
| Deferred Income Taxes | 0,0.00 | |||
| Other Non-Current Liabilities | 0,0.00 | |||
| Minority Interest | 0,0.00 | |||
| Total Non-Current Liabilities | 0,0.00 | |||
| Preferred Stock Equity | 0,0.00 | |||
| Common Stock Equity | 0,0.00 | |||
| Common Par | 0,0.00 | |||
| Additional Paid In Capital | 0,0.00 | |||
| Cumulative Translation Adjustment | 0,0.00 | |||
| Retained Earnings | 0,0.00 | |||
| Treasury Stock | 0,0.00 | |||
| Other Equity Adjustments | 0,0.00 | |||
| Total Capitalization | 0,0.00 | |||
| TOTAL EQUITY | 0,0.00 | |||
| TOTAL LIABILITIES & STOCK EQUITY | 0,0.00 | |||
| Total Common Shares Outstanding | 0,0.00 | |||
| Preferred Shares | 0,0.00 | |||
| Treasury Shares | 0,0.00 | |||
| Basic Weighted Shares Outstanding | 0,0.00 | |||
| Diluted Weighted Shares Outstanding | 0,0.00 | |||
| Number Of Employees | 0,0.00 | |||
| Number Of Part-Time Employees | 0,0.00 | |||
TOTAL REVENUES |
EBT Excluding Unusual Items |
NET INCOME |
|---|---|---|
Income Statement
| M Y | |
|---|---|
| Sales | 0,0.00 |
| Cost Of Sales | 0,0.00 |
| Gross Operating Profit | 0,0.00 |
| Selling, General, And Administrative Expenses | 0,0.00 |
| Research & Development | 0,0.00 |
| Operating Income Before D & A (EBITDA) | 0,0.00 |
| Depreciation & Amortization | 0,0.00 |
| Interest Income | 0,0.00 |
| Other Income - Net | 0,0.00 |
| Special Income / Charges | 0,0.00 |
| Total Income Before Interest Expenses (EBIT) | 0,0.00 |
| Interest Expense | 0,0.00 |
| Pre-Tax Income | 0,0.00 |
| Income Taxes | 0,0.00 |
| Minority Interest | 0,0.00 |
| Net Income From Continuing Operations | 0,0.00 |
| Net Income From Discontinued Operations | 0,0.00 |
| Net Income From Total Operations | 0,0.00 |
| Extraordinary Income/Losses | 0,0.00 |
| Income From Cum. Effect Of Acct. Change | 0,0.00 |
| Income From Tax Loss Carryforward | 0,0.00 |
| Other Gains / Losses | 0,0.00 |
| Total Net Income | 0,0.00 |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
0,0.00 |
| Preferred Dividends | 0,0.00 |
| Net Income Available To Common | 0,0.00 |
| Basic EPS From Continuing Ops. | 0,0.00 |
| Basic EPS From Discontinued Ops. | 0,0.00 |
| Basic EPS From Total Operations | 0,0.00 |
| Basic EPS From Extraordinary Inc. | 0,0.00 |
| Basic EPS From Cum Effect Of Accounting Change | 0,0.00 |
| Basic EPS From Tax Loss Carryf'd. | 0,0.00 |
| Basic EPS From Other Gains (Losses) | 0,0.00 |
| Basic EPS, Total | 0,0.00 |
| Basic Normalized Net Income/Share | 0,0.00 |
| EPS From Continuing Ops. | 0,0.00 |
| EPS From Discontinued Ops | 0,0.00 |
| EPS From Total Ops. | 0,0.00 |
| EPS From Extraord. Inc. | 0,0.00 |
| EPS From Cum Effect of Accounting Change | 0,0.00 |
| EPS From Tax Loss Carfd. | 0,0.00 |
| EPS From Other Gains (L) | 0,0.00 |
| EPS, Total | 0,0.00 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
0,0.00 |
| Dividends Paid Per Share | 0,0.00 |
CASH FROM OPERATIONS |
CASH FROM INVESTING ACTIVITIES |
CASH FROM FINANCING ACTIVITIES |
|---|---|---|
Cash Flow Statement
| M Y | ||||
|---|---|---|---|---|
| Cash Flow From Operating Activities | ||||
| Net Income (Loss) | 0,0.00 | |||
| Operating Gains/Losses | 0,0.00 | |||
| Gross Operating Profit | 0,0.00 | |||
| (Increase) Decrease In Receivables | 0,0.00 | |||
| (Increase) Decrease In Inventories | 0,0.00 | |||
| (Increase) Decrease In Other Current Assets | 0,0.00 | |||
| (Decrease) Increase In Other Current Liabilities | 0,0.00 | |||
| (Increase) Decrease In Other Working Capital | 0,0.00 | |||
| Other Non-Cash Items | 0,0.00 | |||
| Net Cash From Continuing Operations | 0,0.00 | |||
| Net Cash From Discontinued Operations | 0,0.00 | |||
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | 0,0.00 | |||
| Sale Of Property, Plant & Equipment | 0,0.00 | |||
| Cash Used For Investing Activities | ||||
| Sale Of Short-Term Investments | 0,0.00 | |||
| Purchases Of Property, Plant & Equipment | 0,0.00 | |||
| Acquisitions | 0,0.00 | |||
| Purchases Of Short-Term Investments | 0,0.00 | |||
| Other Cash From Investing Activities | 0,0.00 | |||
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | 0,0.00 | |||
| Issuance Of Debt | 0,0.00 | |||
| Cash Used For Financing Activities | ||||
| Issuance Of Capital Stock | 0,0.00 | |||
| Repayment Of Long-Term Debt | 0,0.00 | |||
| Repurchase Of Capital Stock | 0,0.00 | |||
| Payment Of Cash Dividends | 0,0.00 | |||
| Other Financing Charges, Net | 0,0.00 | |||
| Net Cash From Financing Activities | 0,0.00 | |||
| Effect Of Exchange Rate Changes | 0,0.00 | |||
| Net Change In Cash & Cash Equivalents | 0,0.00 | |||
Earnings Estimates
as of 4:00 ET PM 09/16/2021| Current Qtr (09/2021) |
Next Qtr (12/2021) |
|
|---|---|---|
| Consensus Estimate | $0.37 | $0.36 |
| # of Estimates | 3 | 3 |
| High Estimate | $0.41 | $0.37 |
| Low Estimate | $0.35 | $0.33 |
| Year Ago EPS | $0.42 | $0.38 |
| Year Over Year Growth Estimate | -11.41% | -6.02% |
| Current Yr (03/2022) |
Next Yr (03/2023) |
|
|---|---|---|
| Consensus Estimate | $1.33 | $1.54 |
| # of Estimates | 3 | 3 |
| High Estimate | $1.35 | $1.62 |
| Low Estimate | $1.30 | $1.41 |
| Year Ago EPS | $1.52 | $1.33 |
| Year Over Year Growth Estimate | -12.62% | 16.31% |
| Current Qtr (09/2021) |
Next Qtr (12/2021) |
Current Year (03/2022) |
Next Year (03/2023) |
|
|---|---|---|---|---|
| Consensus Estimate | $0.37 | $0.36 | $1.33 | $1.54 |
| # of Estimates | 3 | 3 | 3 | 3 |
| High Estimate | $0.41 | $0.37 | $1.35 | $1.62 |
| Low Estimate | $0.35 | $0.33 | $1.30 | $1.41 |
| Year Ago EPS | $0.42 | $0.38 | $1.52 | $1.33 |
| Year Over Year Growth Estimate | -11.41% | -6.02% | -12.62% | 16.31% |
Insider Information Summary
as of 08/31/2021| % Insiders - 6.55% | |
| % Remaining Total Shares - 93.45% |
| Current | 1 Month | |
|---|---|---|
| Net Insider Transaction | 38.93 K | 38.93 K |
| Shares Bought | 44.93 K | 44.93 K |
| Shares Sold | 6.00 K | 6.00 K |
Insider Activity
| Transaction Date | Insider/Title | Transaction Type | Market Value | Shares | Average Price | Current Holdings | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Trade with Jim Cramer 14 Days Free
Join the Action Alerts PLUS Community today!
LATEST NEWS
Latest News
Focus on Financials: Cramer's 'Mad Money' Recap (Wednesday 8/19/20)
- Aug 20, 2020 4:58 AM EDT
PetMed Drops Following First-Quarter Miss on Increased Online Competition
- Jul 22, 2019 10:02 AM EDT
Walmart Launches Online Pet Pharmacy, Expands In-Store Vet Clinics
- May 7, 2019 12:55 PM EDT
Wheaton Precious Metals, PetMed Express: 'Mad Money' Lightning Round
- May 2, 2019 8:55 PM EDT
Don't Forget the Consumer: Cramer's 'Mad Money' Recap
- Oct 24, 2018 11:04 PM EDT
Blackberry, SkyWest, Apache: 'Mad Money' Lightning Round
- Apr 7, 2018 7:08 AM EDT
PetMed Express, STMicroelectronics: 'Mad Money' Lightning Round
- Feb 27, 2018 6:28 AM EST
3 Pet Stocks That Could Surge After General Mills Deal for Blue Buffalo
- Feb 23, 2018 1:03 PM EST
Meet TheStreet's Pets! They May Be Expensive -- But We Love Them!
- Dec 23, 2017 8:30 AM EST
Recent Articles from TheStreet
Intraday Reversals Signal Struggles for Market
But James "Rev Shark" Deporre says the trading action is both normal, and appropriate for September, and he's been adding some names to his portfolio.
Cramer's Mad Money Recap: FedEx, Costco, Nike
Jim Cramer says this is a rough season for stock, and investors need to take defensive action.
Jensen: Economy Has a Bearish Outlook
Real Money's Bret Jensen says a slower-than-expected pandemic recovery is a warning for the stock market.
FDA Panel Recommends Covid Booster Shots for 65, Older and Those at High Risk
Food and Drug Administration's advisory panel on Friday voted to recommend Covid-19 booster shots of the Pfizer vaccine for a limited section of the population.
Stock Market Today With Jim Cramer: How to Trade Ford
Jim Cramer discusses Ford and the impact of the impending tax policy changes on the stock market.
Thermo Fisher Climbs on Strong 2022 Guidance
Thermo Fisher expects revenue to increase 12% year over year next year to $40.3 billion.
CLOSE
CLOSE
CLOSE
CLOSE